Publications by authors named "Gary W Middleton"

Claim this Profile
E
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.
Richard Phillips, Bristi Basu, Zohra Butt, Mounia Beloueche, Natalie Cook, Gary W Middleton

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to editor: Complementary perspectives on B cell regulatory phenotypes in cancer.
Akshay J Patel, Gary W Middleton

Front Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.
Zena N Willsmore, Lucy Booth, Akshay Patel, Ashley Di Meo, Ioannis Prassas, Gary W Middleton

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.
Daniel H Palmer, Richard Jackson, Christoph Springfeld, Paula Ghaneh, Charlotte Rawcliffe, Gary William Middleton

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.
Christopher J M Williams, Allyson M Peddle, Pashtoon M Kasi, Jenny F Seligmann, Campbell S Roxburgh, Gary W Middleton

Nat Rev Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.
Christopher J M Williams, Allyson M Peddle, Pashtoon M Kasi, Jenny F Seligmann, Campbell S Roxburgh, Gary W Middleton

Nat Rev Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep immune B and plasma cell repertoire in non-small cell lung cancer.
Akshay J Patel, Naeem Khan, Alex Richter, Babu Naidu, Mark T Drayson, Gary W Middleton

Front Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIGIT-based immunotherapeutics in lung cancer.
Akshay J Patel, Gary W Middleton

Immunother Adv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.
Akshay J Patel, Zena N Willsmore, Naeem Khan, Alex Richter, Babu Naidu, Gary W Middleton

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.
Akshay J Patel, Ti-Myen Tan, Alex G Richter, Babu Naidu, Jonathan M Blackburn, Gary W Middleton

Br J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
Regina Andrijes, Rahul K Hejmadi, Matthew Pugh, Sundaresan Rajesh, Vera Novitskaya, Gary W Middleton

Proc Natl Acad Sci U S A· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer.
Oliver J Pickles, Aneta Drozd, Louise Tee, Andrew D Beggs, Gary W Middleton

Oncotarget· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies.
Akshay J Patel, Peter Nightingale, Babu Naidu, Mark T Drayson, Gary W Middleton

J Thorac Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer.
Akshay J Patel, Alex Richter, Mark T Drayson, Gary W Middleton

Cancer Immunol Immunother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Robert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, Paula Ghaneh, Christopher M Halloran, Gary William Middleton

JAMA Surg· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic loss of heterozygosity and survival in the REAL3 trial.
Elizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, Tom Waddell, Ruwaida Begum, Gary W Middleton

Oncotarget· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
Neeraj Lal, Brian S White, Ghaleb Goussous, Oliver Pickles, Mike J Mason, Gary W Middleton

Clin Cancer Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Gary William Middleton

Lancet· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.
Andrew D Beggs, Mark P Dilworth, Enric Domingo, Rachel Midgley, David Kerr, Gary W Middleton

Oncoscience· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy.
Neeraj Lal, Andrew D Beggs, Benjamin E Willcox, Gary W Middleton

Oncoimmunology· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Hugo E R Ford, Andrea Marshall, John A Bridgewater, Tobias Janowitz, Fareeda Y Coxon, Gary W Middleton

Lancet Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Gary W Middleton, Nicola E Annels, Hardev S Pandha

Cancer Immunol Immunother· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
Rachel F Gabitass, Nicola E Annels, Deborah D Stocken, Hardev A Pandha, Gary W Middleton

Cancer Immunol Immunother· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic rectal adenocarcinoma within haemorrhoids: a case report.
Dorothy M Gujral, Sanjeev Bhattacharyya, Peter Hargreaves, Gary W Middleton

J Med Case Rep· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Periodontal disease in a patient receiving Bevacizumab: a case report.
Dorothy M Gujral, Sanjeev Bhattacharyya, Peter Hargreaves, Gary W Middleton

J Med Case Rep· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis